ArticleMolecular biotechnology2026
Pentavalent Recombinant Vaccine Using Escherichia coli Bacterins Against Major Clostridium Toxins in Ruminants.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium perfringens and Clostridium botulinum are anaerobic spore-forming bacteria that produce potent toxins and are major causative agents of severe toxicoinfections in ruminants. Although vaccination remains the primary preventive strategy, current commercial vaccines are based on crude toxoid preparations, which present several limitations, including labor-intensive manufacturing processes, high biological risk, and batch-to-batch variability. This study aimed to evaluate the immunogenicity of a pentavalent recombinant bacterin vaccine formulation containing antigens derived from C. perfringens (CPA, CPB, and ETX) and C. botulinum (BoNT/C and BoNT/D) in cattle, sheep, goats, and buffaloes. Individual and chimeric recombinant antigens were expressed in Escherichia coli and incorporated into a vaccine formulation containing three inactivated bacterial components (bacterins) adsorbed onto aluminum hydroxide. A total of 92 ruminants (23 cattle, 23 buffaloes, 23 sheep, and 23 goats) were included in the study and allocated to receive the recombinant vaccine, a commercial vaccine, or saline as a negative control. Neutralizing antibody titers were determined by serum neutralization assays. The recombinant vaccine was well tolerated across all species and induced neutralizing antibody titers of 10 IU/mL against CPB, 5 IU/mL against BoNT/C, and 4 IU/mL against BoNT/D. The response to ETX was species-dependent, with cattle and sheep reaching antibody titers of 4 IU/mL, whereas buffaloes and goats reached 2 IU/mL. Neither the recombinant bacterin nor the commercial vaccine elicited detectable neutralizing antibody responses against CPA, highlighting the need for further strategies to improve the immunogenicity of this antigen. Nevertheless, the overall findings support the potential of the pentavalent recombinant vaccine to confer protective immunogenicity against multiple clostridial toxins. Incorporating recombinant nontoxic antigenic domains into a bacterin-based platform represents a safe, scalable, and antigen-sparing alternative to conventional toxoid vaccines, with promising implications for improving the prevention and control of clostridial diseases in ruminant livestock.
Indexed as
Identifiers
42842087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.